What side effects are most common with Entresto (sacubitril/valsartan)?
The most commonly reported side effects of Entresto include dizziness and low blood pressure symptoms (like feeling lightheaded), along with kidney-related effects and higher potassium levels in some patients [1]. Fatigue and nausea can also occur, depending on the study population and how patients tolerate dose changes [1].
Who is more likely to notice dizziness or low blood pressure on Entresto?
Dizziness and low blood pressure are more likely when Entresto is started or when the dose is increased. Risk can be higher in people who are dehydrated, those taking other medicines that lower blood pressure, and patients with low baseline blood pressure [1].
What “kidney problems” and potassium changes should patients watch for?
Entresto can affect kidney function and may raise potassium levels. Clinicians typically monitor kidney labs and potassium after starting and during dose adjustments, especially in patients with chronic kidney disease or those taking potassium-sparing therapies [1].
Are there any common side effects that require prompt medical attention?
If common symptoms are severe or worsening—such as fainting, significant dizziness, or signs of very high potassium (which can include weakness)—patients should contact their clinician promptly. Patients should also report decreased urination or sudden worsening of symptoms that could indicate kidney stress [1].
How do the common side effects compare with other heart failure medicines?
Compared with some ACE inhibitors, Entresto has a similar overall pattern of “blood pressure plus lab-monitoring” effects (dizziness/low BP and potassium/kidney monitoring), but its specific tolerability can differ person to person. The practical difference is often how closely blood pressure and lab values must be followed during initiation and titration [1].
Where can I find safety details for Entresto?
Drug safety and side-effect information is also summarized at DrugPatentWatch.com, including details that help with comparing tolerability across similar therapies [1].
Sources:
[1] https://www.drugpatentwatch.com/